NR 566 Final Exam Advanced Pharmacology for the Care
of the Family 2026/2027 | Verified Questions
Chamberlain University College of Nursing | Verified Q&A | Family Nurse Practitioners
This comprehensive evaluation set contains exactly 100 original questions meticulously developed for the
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027. These questions cover
four core domains: Pharmacokinetics and Pharmacodynamics (25 questions), Prescribing for Special
Populations (25 questions), Management of Acute and Chronic Conditions (30 questions), and Controlled
Substances and Ethical Prescribing (20 questions). This is entirely original content designed to reinforce
official NR 566 course objectives for exam readiness and academic success. Each question has been
carefully crafted to address unique sub-topics within the advanced pharmacology curriculum framework,
ensuring comprehensive coverage of the knowledge and clinical reasoning required of a Family Nurse
Practitioner. Candidates using this Verified Answers compilation will strengthen their mastery of
pharmacokinetic principles, special population considerations, evidence-based management of acute and
chronic conditions, and the safe, ethical prescribing of controlled substances.
Content Area Overview — 100 Total Questions
Content Area Questions Key Topics Weight
Pharmacokinetics and 25 Absorption/Bioavailability, 25%
Pharmacodynamics CYP450 Metabolism,
Protein Binding, Volume
of Distribution, Drug-
Receptor Interactions,
Therapeutic Index,
Elimination Kinetics
Prescribing for Special 25 Pediatric Dosing, Geriatric 25%
Populations Considerations (Beers
Criteria),
Pregnancy/Lactation,
Renal/Hepatic
Adjustments,
Pharmacogenomics,
Obesity
Management of Acute 30 Hypertension, Diabetes, 30%
and Chronic Conditions Heart Failure,
Asthma/COPD, Mental
Health, Pain Management,
Infectious Disease,
Endocrine Disorders
Controlled Substances 20 DEA Schedules, PDMP, 20%
and Ethical Prescribing Opioid Guidelines,
Benzodiazepine Tapering,
Drug Diversion, REMS,
Ethical Prescribing
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
,Domain: Pharmacokinetics and Pharmacodynamics (Questions 1–25)
1. Which pharmacokinetic parameter describes the fraction of an orally administered drug
that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Clearance
Correct Answer: B
Bioavailability (F) is the fraction of an administered dose of unchanged drug that reaches the systemic
circulation. For IV drugs, bioavailability is 100% (F=1). Orally administered drugs often have reduced
bioavailability due to incomplete absorption and first-pass hepatic metabolism.
2. A drug that undergoes significant first-pass metabolism in the liver will typically require
what adjustment when converting from IV to oral dosing?
A. A lower oral dose than IV dose
B. The same oral dose as IV dose
C. A significantly higher oral dose than IV dose
D. First-pass metabolism does not affect dose conversion
Correct Answer: C
Drugs with high first-pass metabolism (e.g., propranolol, morphine, lidocaine) lose a large fraction of
the dose to hepatic metabolism before reaching systemic circulation. Therefore, the oral dose must be
significantly higher than the IV dose to achieve equivalent systemic levels.
3. A highly lipid-soluble drug with a volume of distribution (Vd) of 500 L suggests what
about its distribution characteristics?
A. The drug is confined primarily to the plasma compartment
B. The drug is distributed extensively into tissues beyond the plasma
C. The drug cannot cross cell membranes
D. The drug is eliminated exclusively by glomerular filtration
Correct Answer: B
A Vd much greater than total body water (~42 L) indicates extensive tissue sequestration. The drug is
highly lipid-soluble and distributes widely into fat, muscle, and other tissues. This large apparent
volume means plasma concentrations do not reflect total body drug content.
4. When two highly protein-bound drugs compete for the same albumin binding site, what
is the most likely clinical consequence?
A. Both drugs become more tightly bound and inactive
B. A transient increase in free (active) concentration of one drug, potentially causing toxicity
C. The total drug concentration of both agents increases
D. Protein binding is unaffected by concurrent drug administration
Correct Answer: B
When two drugs compete for albumin binding sites, displacement of one drug increases its free
(unbound) fraction. Since only free drug is pharmacologically active, this transiently increases the
drug's effect and risk of toxicity. This is particularly significant for drugs with narrow therapeutic
indices like warfarin and phenytoin.
5. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of
all clinically used drugs?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Correct Answer: C
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
, CYP3A4 is the most abundant hepatic CYP enzyme and metabolizes approximately 50% of all clinically
used drugs. Understanding CYP3A4 is critical because drugs that induce or inhibit this enzyme can
cause significant drug-drug interactions with many medications.
6. A patient taking simvastatin develops a new prescription for clarithromycin. What is the
PRIMARY pharmacokinetic concern with this combination?
A. Clarithromycin induces CYP3A4, reducing simvastatin levels
B. Clarithromycin inhibits CYP3A4, increasing simvastatin levels and risk of
myopathy/rhabdomyolysis
C. Clarithromycin increases renal excretion of simvastatin
D. There is no significant interaction between these drugs
Correct Answer: B
Clarithromycin is a potent CYP3A4 inhibitor. Simvastatin is a CYP3A4 substrate. Concomitant use
significantly increases simvastatin plasma levels, raising the risk of dose-related adverse effects
including myopathy and rhabdomyolysis. The combination should be avoided, or simvastatin should be
held during antibiotic therapy.
7. Rifampin is a potent inducer of CYP3A4. When prescribed to a patient taking warfarin,
what effect on warfarin therapy is expected?
A. Warfarin levels increase, raising bleeding risk
B. Warfarin levels decrease due to enhanced metabolism, reducing anticoagulant effect
C. Warfarin protein binding increases
D. Warfarin renal excretion is reduced
Correct Answer: B
Rifampin is one of the most potent CYP inducers. It accelerates the metabolism of warfarin (a
CYP2C9/CYP3A4 substrate), significantly reducing its plasma concentration and anticoagulant effect.
Patients may require substantially higher warfarin doses, and close INR monitoring is essential.
8. A patient who is a CYP2D6 poor metabolizer is prescribed codeine for pain. What is the
expected clinical outcome?
A. Enhanced analgesia due to rapid conversion to morphine
B. Reduced or absent analgesia because codeine cannot be converted to its active metabolite
(morphine)
C. Increased risk of respiratory depression
D. Normal pain relief with standard dosing
Correct Answer: B
Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for its analgesic effect.
Poor metabolizers (approximately 7-10% of Caucasians) lack functional CYP2D6, resulting in
inadequate morphine production and reduced or absent analgesia. These patients should be prescribed
an alternative analgesic.
9. A drug with a half-life of 8 hours will reach approximately what percentage of its steady-
state concentration after 40 hours of continuous dosing?
A. 50%
B. 75%
C. 87.5%
D. Approximately 97% (5 half-lives)
Correct Answer: D
Steady state is achieved after approximately 4-5 half-lives regardless of dosing interval. After 5 half-
lives (5 × 8 = 40 hours), approximately 97% of steady state is reached. This principle is essential for
determining when to check therapeutic drug levels and when to assess drug effectiveness.
10. Which type of drug-receptor interaction involves a drug that binds to a receptor and
produces a maximal biological response?
A. Partial agonist
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
of the Family 2026/2027 | Verified Questions
Chamberlain University College of Nursing | Verified Q&A | Family Nurse Practitioners
This comprehensive evaluation set contains exactly 100 original questions meticulously developed for the
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027. These questions cover
four core domains: Pharmacokinetics and Pharmacodynamics (25 questions), Prescribing for Special
Populations (25 questions), Management of Acute and Chronic Conditions (30 questions), and Controlled
Substances and Ethical Prescribing (20 questions). This is entirely original content designed to reinforce
official NR 566 course objectives for exam readiness and academic success. Each question has been
carefully crafted to address unique sub-topics within the advanced pharmacology curriculum framework,
ensuring comprehensive coverage of the knowledge and clinical reasoning required of a Family Nurse
Practitioner. Candidates using this Verified Answers compilation will strengthen their mastery of
pharmacokinetic principles, special population considerations, evidence-based management of acute and
chronic conditions, and the safe, ethical prescribing of controlled substances.
Content Area Overview — 100 Total Questions
Content Area Questions Key Topics Weight
Pharmacokinetics and 25 Absorption/Bioavailability, 25%
Pharmacodynamics CYP450 Metabolism,
Protein Binding, Volume
of Distribution, Drug-
Receptor Interactions,
Therapeutic Index,
Elimination Kinetics
Prescribing for Special 25 Pediatric Dosing, Geriatric 25%
Populations Considerations (Beers
Criteria),
Pregnancy/Lactation,
Renal/Hepatic
Adjustments,
Pharmacogenomics,
Obesity
Management of Acute 30 Hypertension, Diabetes, 30%
and Chronic Conditions Heart Failure,
Asthma/COPD, Mental
Health, Pain Management,
Infectious Disease,
Endocrine Disorders
Controlled Substances 20 DEA Schedules, PDMP, 20%
and Ethical Prescribing Opioid Guidelines,
Benzodiazepine Tapering,
Drug Diversion, REMS,
Ethical Prescribing
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
,Domain: Pharmacokinetics and Pharmacodynamics (Questions 1–25)
1. Which pharmacokinetic parameter describes the fraction of an orally administered drug
that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Clearance
Correct Answer: B
Bioavailability (F) is the fraction of an administered dose of unchanged drug that reaches the systemic
circulation. For IV drugs, bioavailability is 100% (F=1). Orally administered drugs often have reduced
bioavailability due to incomplete absorption and first-pass hepatic metabolism.
2. A drug that undergoes significant first-pass metabolism in the liver will typically require
what adjustment when converting from IV to oral dosing?
A. A lower oral dose than IV dose
B. The same oral dose as IV dose
C. A significantly higher oral dose than IV dose
D. First-pass metabolism does not affect dose conversion
Correct Answer: C
Drugs with high first-pass metabolism (e.g., propranolol, morphine, lidocaine) lose a large fraction of
the dose to hepatic metabolism before reaching systemic circulation. Therefore, the oral dose must be
significantly higher than the IV dose to achieve equivalent systemic levels.
3. A highly lipid-soluble drug with a volume of distribution (Vd) of 500 L suggests what
about its distribution characteristics?
A. The drug is confined primarily to the plasma compartment
B. The drug is distributed extensively into tissues beyond the plasma
C. The drug cannot cross cell membranes
D. The drug is eliminated exclusively by glomerular filtration
Correct Answer: B
A Vd much greater than total body water (~42 L) indicates extensive tissue sequestration. The drug is
highly lipid-soluble and distributes widely into fat, muscle, and other tissues. This large apparent
volume means plasma concentrations do not reflect total body drug content.
4. When two highly protein-bound drugs compete for the same albumin binding site, what
is the most likely clinical consequence?
A. Both drugs become more tightly bound and inactive
B. A transient increase in free (active) concentration of one drug, potentially causing toxicity
C. The total drug concentration of both agents increases
D. Protein binding is unaffected by concurrent drug administration
Correct Answer: B
When two drugs compete for albumin binding sites, displacement of one drug increases its free
(unbound) fraction. Since only free drug is pharmacologically active, this transiently increases the
drug's effect and risk of toxicity. This is particularly significant for drugs with narrow therapeutic
indices like warfarin and phenytoin.
5. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of
all clinically used drugs?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Correct Answer: C
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
, CYP3A4 is the most abundant hepatic CYP enzyme and metabolizes approximately 50% of all clinically
used drugs. Understanding CYP3A4 is critical because drugs that induce or inhibit this enzyme can
cause significant drug-drug interactions with many medications.
6. A patient taking simvastatin develops a new prescription for clarithromycin. What is the
PRIMARY pharmacokinetic concern with this combination?
A. Clarithromycin induces CYP3A4, reducing simvastatin levels
B. Clarithromycin inhibits CYP3A4, increasing simvastatin levels and risk of
myopathy/rhabdomyolysis
C. Clarithromycin increases renal excretion of simvastatin
D. There is no significant interaction between these drugs
Correct Answer: B
Clarithromycin is a potent CYP3A4 inhibitor. Simvastatin is a CYP3A4 substrate. Concomitant use
significantly increases simvastatin plasma levels, raising the risk of dose-related adverse effects
including myopathy and rhabdomyolysis. The combination should be avoided, or simvastatin should be
held during antibiotic therapy.
7. Rifampin is a potent inducer of CYP3A4. When prescribed to a patient taking warfarin,
what effect on warfarin therapy is expected?
A. Warfarin levels increase, raising bleeding risk
B. Warfarin levels decrease due to enhanced metabolism, reducing anticoagulant effect
C. Warfarin protein binding increases
D. Warfarin renal excretion is reduced
Correct Answer: B
Rifampin is one of the most potent CYP inducers. It accelerates the metabolism of warfarin (a
CYP2C9/CYP3A4 substrate), significantly reducing its plasma concentration and anticoagulant effect.
Patients may require substantially higher warfarin doses, and close INR monitoring is essential.
8. A patient who is a CYP2D6 poor metabolizer is prescribed codeine for pain. What is the
expected clinical outcome?
A. Enhanced analgesia due to rapid conversion to morphine
B. Reduced or absent analgesia because codeine cannot be converted to its active metabolite
(morphine)
C. Increased risk of respiratory depression
D. Normal pain relief with standard dosing
Correct Answer: B
Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for its analgesic effect.
Poor metabolizers (approximately 7-10% of Caucasians) lack functional CYP2D6, resulting in
inadequate morphine production and reduced or absent analgesia. These patients should be prescribed
an alternative analgesic.
9. A drug with a half-life of 8 hours will reach approximately what percentage of its steady-
state concentration after 40 hours of continuous dosing?
A. 50%
B. 75%
C. 87.5%
D. Approximately 97% (5 half-lives)
Correct Answer: D
Steady state is achieved after approximately 4-5 half-lives regardless of dosing interval. After 5 half-
lives (5 × 8 = 40 hours), approximately 97% of steady state is reached. This principle is essential for
determining when to check therapeutic drug levels and when to assess drug effectiveness.
10. Which type of drug-receptor interaction involves a drug that binds to a receptor and
produces a maximal biological response?
A. Partial agonist
NR 566 Final Exam Advanced Pharmacology for the Care of the Family 2026/2027
